Jakub Wójcik Selected Research

Neoplasms (Cancer)

1/2022	Deprogramming metabolism in pancreatic cancer with a bi-functional GPR55 inhibitor and biased β2 adrenergic agonist.
12/2021	Gene Expression Data Mining Reveals the Involvement of GPR55 and Its Endogenous Ligands in Immune Response, Cancer, and Differentiation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jakub Wójcik Research Topics

Disease

2	Neoplasms (Cancer) 01/2022 - 12/2021
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022

Drug/Important Bio-Agent (IBA)

1	ophthalmic acidIBA 01/2022
1	pyrimidineIBA 01/2022
1	Adrenergic Agonists (Adrenergic Receptor Agonist)IBA 01/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2022
1	alpha-aminobutyric acidIBA 01/2022
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2022
1	Glutamic Acid (Glutamate)FDA Link 01/2022
1	LigandsIBA 12/2021